Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 16/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CCNH | P51946 | 1/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703349 | 0.94 | IRAK4 (0.44) | GPR6IRAK4CDK1CDK4CCND1 | |
| SCHEMBL703968 | 0.87 | JAK2 (0.38) | GPR6IRAK4CDK2CCNT1CCNE1 | |
| SCHEMBL698566 | 0.87 | JAK2 (0.39) | GPR6IRAK4CDK1CDK4CCND1 | |
| SCHEMBL706896 | 0.86 | MAPK14 (0.43) | IRAK4CDK1CDK4CCND1CDK2 | |
| SCHEMBL703800 | 0.86 | IRAK4 (0.44) | GPR6IRAK4CDK1CDK4CCND1 | |
| SCHEMBL708407 | 0.85 | MAPK14 (0.43) | CDK1CDK4CCND1CDK2CCNB1 | |
| SCHEMBL703045 | 0.84 | MAPK14 (0.51) | GPR6CDK1CDK4CCND1CDK2 | |
| SCHEMBL704772 | 0.83 | CDK2 (0.44) | CDK1CDK4CCND1CDK2CCNT1 | |
| SCHEMBL31448368 | 0.83 | CDK2 (0.44) | CDK1CDK4CCND1CDK2CCNT1 | |
| SCHEMBL2680449 | 0.82 | MAPK14 (0.43) | CDK1CDK4CCND1CDK2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | GPR6 2369/4885IRAK4 2788/4885CDK1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.